



A LETTER FROM CHRISTI SHAW

Our focus on the cure is extremely personal to me; like so many others, I've lost too many people I love to cancer. I joined Kite in 2019 to help bring therapies with curative intent to patients who desperately need them. We believe cell therapy has the power to change the way cancer is treated, and we are proud to be the first company with multiple chimeric antigen receptor (CAR) T cell therapies for people living with certain types of blood cancer.

For all of us at Kite, a deep sense of connection to the patients we serve is at the heart of everything we do. We are in a unique position to help patients who previously had limited treatment options, and our continued pursuit of potentially life-saving therapies is what drives our entire organization forward. This includes working to ensure our medicines are made available to all people who may be helped by them, regardless of location or cost.

While our industry-leading cell therapy pipeline is currently addressing the unmet need in hematologic cancers, we're also focused on bringing the benefits of cell therapy to patients with solid tumors and advancing next generation allogeneic therapies. I am incredibly proud to be part of a team that is pushing the boundaries of science to make a real and meaningful difference for people impacted by cancer and those who love them.

Christi